


# NiCCC


## Nintedanib in Clear Cell Carcinoma

A Randomised Phase II Study of BIBF 1120 versus  
Chemotherapy in Recurrent Clear Cell Carcinoma of the  
Ovary or Endometrium

SGCTG/NCRI/NSGO



# NiCCC Trial Design




Primary Endpoint: PFS

Secondary Endpoints: OS, Toxicity, RR, QoL, Q-Twist

# Trial Status

- Study opened in the UK April 2015
  - 11 centres are open
  - 12 patients randomised
- GINECO due to open June 2016
- EORTC due to open Sept 2016
- NSGO due to open Oct/Nov 2016

# Recruitment



# Recruitment by Site

Site	Site Number	PI	Date Activated to Recruitment	Anticipated Recruitment Target per year	Total Number of patients to date	Comment
Beatson West of Scotland Cancer Centre, Glasgow	002	Dr Ros Glasspool	02-Apr-15	2	4	
Belfast City Hospital (Northern Ireland Cancer Centre)	015	Dr Sarah McKenna	04-Mar-16	1	0	
Bristol Haematology and Cancer Centre	034	Axel Walther	08-Dec-15	2	1	
Clatterbridge Cancer Centre, Liverpool	007	Dr Rosemary Lord	04-May-16	2	0	1 patient registered for central pathology review
Great Western Hospital, Swindon	070	Dr Omar Khan	04-Sep-15	1	1	
Guy's Hospital, London	010	Dr Ana Montes	17/02/2016	2	1	
Kent & Canterbury Hospital	064	Dr Justin Waters	09-Dec-15	0.5.	1	
Musgrove Park Hospital, Taunton	018	Dr Clare Barlow	12/05/2015	1	1	
Ninewells Hospital, Dundee	062	Dr Michelle Ferguson	17/03/2016	1	0	
Queen Elizabeth Queen Mother Hospital, Kent	063	Dr Justin Waters	09/12/2015	0.5.	0	
Royal Marsden Hosp - Fulham Road	Fulham Rd - 017	Dr Susannah Banerjee	23-Jul-15	0.5.	2	
Royal Marsden Hospital - Sutton	Sutton - 004	Dr Susannah Banerjee	23-Jul-15	0.5.	0	
St James's Hospital, Leeds	008	Dr Geoff Hall	23-Jul-15	2	1	
Velindre Hospital, Cardiff	016	Dr Rachel Jones	27-Nov-15	1	0	1 patient registered for central pathology review
William Harvey Hospital, Kent	065	Dr Justin Waters	09/12/2015	0.5.	0	
<b>Total Recruitment to Date:</b>					<b>12</b>	